secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027263
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q3 net loss $3.5M; cash $23.2M; Phase 3 enrollment >30%, topline mid-2023
--------------------------------------------------------------------------------

- Net loss of $3.5M ($0.18 per share) for Q3 2022 vs $2.3M ($0.12) in Q3 2021.
- Cash $23.2M as of Sep 30, 2022, down from $29.7M at Dec 31, 2021; sufficient through Nov 2023.
- Phase 3 RECOVER trial for brilaroxazine enrolled >30% in US; topline data expected mid-2023.
- Announced $8.5M registered direct offering in September 2022.
- Exploring non-dilutive financing for expansion into bipolar, MDD, ADHD, PAH, IPF indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/rvph20221111_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer